ESPN DeportesPreguntas de temporada baja para los equipos eliminadosESPNAfter another playoff disappointment, what's next for Fever?The Jerusalem PostPrivacy law violated after data of 21,000 special education students leaked, Justice Ministry saysDaily MaverickPOWER CRISIS: Property owners spend millions on diesel as Joburg CBD power outages drive away tenantsZDF heuteAktuelle Pressemitteilungen des ZDFRTP DesportoMundial 2027: Francisco Neto pede Portugal fiel à identidade em LarneTagesschauMindestens 30 Tote bei russischen Angriffen auf Busse in der UkraineCBS NewsCurtis Flowers, wrongfully convicted man who was on death row, dies at 56EngadgetGoogle is doing away with Safety Signal on Pixel WatchGlobal NewsStelco begins issuing layoff notices as first job cuts set to take effect SundayBusiness AMJapan lanceert nieuwe onderzeeër en overweegt kernonderzeeërs als reactie op de maritieme uitbreiding van ChinaIl Sole 24 OrePensioni, in Italia solo il 21% di chi ha un patrimonio sotto i 250mila euro si sente preparato sul tema
The Daily Newsstand · Free, Always
Thursday, October 8, 2026

FSSAI send notices to Dr Reddy's, Nestle Health Science, Amazon, Flipkart over misleading protein supplement

Translate

Food Safety and Standards Authority of India (FSSAI) on Thursday issued notices to Dr Reddy's, Nestle Health Science, Tirupati Wellness, Flipkart, Amazon and Netmeds for selling misleading health supplement products.

FSSAI issues notice to Dr Reddy's, Nestle Health Science

Taking to social media, the food regulator announced action against the companies for non-compliant advertising and claims for the product "CELEVIDA GLP " on e-commerce platforms. The regulator said that the claims printed on the pack, such as muscle strength, immunity support and energy metabolism, can potentially mislead consumers about the product and its health benefits.

According to the regulator, "the product was found to be advertised as 'high protein support for lean muscle preservation during GLP-1/GIP therapies', with claims associating its consumption with GLP-1/GIP therapies and preservation of lean muscle."

View the original on Mint →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.